[{"id":"c537cdaa-ab2e-4d12-a7a6-739ded23e41a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02285816","created_at":"2021-01-18T10:46:19.368Z","updated_at":"2024-07-02T16:35:17.712Z","phase":"Phase 1/2","brief_title":"MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours","source_id_and_acronym":"NCT02285816","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1 • MAGEA3","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["PD-L1 • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Marabex (MAGE-A3 vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 01/22/2015","start_date":" 01/22/2015","primary_txt":" Primary completion: 09/19/2019","primary_completion_date":" 09/19/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"0ed7372c-197f-41fe-bce0-6db0f30c2530","acronym":"Pelican","url":"https://clinicaltrials.gov/study/NCT03773744","created_at":"2021-04-27T08:58:31.456Z","updated_at":"2024-07-02T16:36:32.334Z","phase":"Phase 1b","brief_title":"MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma","source_id_and_acronym":"NCT03773744 - Pelican","lead_sponsor":"Turnstone Biologics, Corp.","biomarkers":" MAGEA3","pipe":"","alterations":" ","tags":["MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Marabex (MAGE-A3 vaccine) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/15/2020","start_date":" 02/15/2020","primary_txt":" Primary completion: 10/30/2020","primary_completion_date":" 10/30/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2021-04-06"},{"id":"f300a0e2-8789-4980-a047-3b4280d68a5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879760","created_at":"2021-01-18T14:08:14.143Z","updated_at":"2024-07-02T16:36:40.338Z","phase":"Phase 1/2","brief_title":"Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients","source_id_and_acronym":"NCT02879760","lead_sponsor":"Turnstone Biologics, Corp.","biomarkers":" ALK • MAGEA3","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["ALK • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Marabex (MAGE-A3 vaccine)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/08/2017","start_date":" 03/08/2017","primary_txt":" Primary completion: 02/15/2020","primary_completion_date":" 02/15/2020","study_txt":" Completion: 05/24/2020","study_completion_date":" 05/24/2020","last_update_posted":"2020-10-06"}]